Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E18.76 EPS (ttm)2.88 Insider Own0.20% Shs Outstand1.66B Perf Week-1.81%
Market Cap89.91B Forward P/E17.21 EPS next Y3.14 Insider Trans-5.04% Shs Float1.65B Perf Month1.16%
Income4.84B PEG2.04 EPS next Q0.73 Inst Own71.80% Short Float1.12% Perf Quarter-1.24%
Sales19.97B P/S4.50 EPS this Y184.60% Inst Trans-1.85% Short Ratio1.88 Perf Half Y-4.55%
Book/sh8.67 P/B6.24 EPS next Y6.72% ROA14.50% Target Price57.18 Perf Year-23.56%
Cash/sh3.68 P/C14.72 EPS next 5Y9.19% ROE31.60% 52W Range46.01 - 77.12 Perf YTD-7.43%
Dividend1.56 P/FCF179.83 EPS past 5Y4.20% ROI20.00% 52W High-29.85% Beta1.20
Dividend %2.88% Quick Ratio1.40 Sales past 5Y-1.80% Gross Margin74.30% 52W Low17.58% ATR0.75
Employees25000 Current Ratio1.60 Sales Q/Q12.30% Oper. Margin31.60% RSI (14)41.63 Volatility1.52% 1.41%
OptionableYes Debt/Eq0.59 EPS Q/Q32.40% Profit Margin24.20% Rel Volume0.46 Prev Close54.02
ShortableYes LT Debt/Eq0.50 EarningsApr 27 BMO Payout52.80% Avg Volume9.80M Price54.10
Recom2.40 SMA20-1.45% SMA50-1.47% SMA200-2.24% Volume4,461,910 Change0.15%
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
May-22-17 08:15AM  Blog Coverage: Bristol-Myers Squibs Received EMA Validation of Sprycel for the Treatment in Children with Chronic Myelogenous Leukemia Accesswire
07:36AM  What Orencia Meant to BMY in 1Q17 Market Realist
May-19-17 05:48PM  New Research Reports for Britol-Myers, Pricline & Phillips 66 Zacks
05:24PM  Top 5 Buys of Market-Beating Investors at Primecap Management GuruFocus.com
10:36AM  Behind BMYs Cardiovascular Performance in 1Q17 Market Realist
09:06AM  Revisiting Bristol-Myers Squibbs Virology in 1Q17 Market Realist
08:13AM  European Medicines Agency Validates Application for Bristol-Myers Squibbs Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia Business Wire
07:36AM  What Happened to Bristol-Myers Squibbs Opdivo in 1Q17? Market Realist
May-18-17 04:50PM  The Hot Stock: Incyte Climbs Barrons.com
10:37AM  Understanding Bristol-Myers Squibbs Oncology Performance in 1Q17 Market Realist
09:57AM  Biotech Movers: Fast Track Designation Sends Sage Shares Higher TheStreet.com
09:07AM  Behind Bristol-Myers Squibbs 1Q17 Performance Market Realist
07:37AM  Inside Bristol-Myers Squibbs Valuation after the 1Q17 Earnings Market Realist
06:21AM  What to watch at ASCO cancer conference CNBC Videos
May-17-17 05:00PM  Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 Business Wire
12:39PM  Eli Lilly: Worries Ahead In Patent Fight Barrons.com
May-16-17 12:30PM  Cramer: Carl Icahn Was Right to Sell Apple at $95 TheStreet.com
12:30PM  Carl Icahn Was Right to Sell Apple at $95 TheStreet.com
12:17PM  Eli Lilly: Has This Bloom Begun To Wilt? Barrons.com
06:59AM  Bristol-Myers Squibb to Take Part in UBS Global Healthcare Conference Business Wire
May-14-17 03:03PM  Retired? 3 Stocks You Should Consider Buying Motley Fool
May-12-17 05:00PM  Johnson & Johnson Analyst Day Yahoo Finance Video
May-11-17 11:52AM  Here's What The FDA Approval Of Keytruda Means For Merck, And For Bristol-Myers Benzinga
11:20AM  Merck: Seal of Approval? Barrons.com
06:55AM  Human Antibody Discovery: Of Mice And Phage Forbes
May-10-17 07:43PM  Why Roche's Cancer Failure Might Tank Bristol, Pfizer But Not Merck Investor's Business Daily
06:12PM  U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer Reuters
03:13PM  Here's Why Calithera Biosciences Stock Gained as Much as 16.4% Today Motley Fool
10:30AM  Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up Zacks
08:19AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : May 10, 2017 Capital Cube
06:59AM  Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma Business Wire
05:50AM  Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers TheStreet.com
May-09-17 05:41PM  Celldex Therapeutics, Inc.'s Collaboration with Bristol-Myers Squibb Key in First-Quarter Update Motley Fool
01:00PM  Buy 'repatriation stocks' because that is sure to make the cut in the final tax bill, UBS says CNBC
May-08-17 09:34AM  J&J: What's In Store At Next Week's Analyst Meeting Barrons.com
May-06-17 09:03AM  Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers Benzinga
May-03-17 04:31PM  Bristol-Myers 'Too Risky' To Acquire As Merck, Roche Pile On Pressure Investor's Business Daily
02:52PM  Bristol-Myers Stock Falls Following Ratings Cut at BMO TheStreet.com
10:33AM  Bristol-Myers: Going Stag to the Ball? Barrons.com
09:12AM  Analysts' Actions -- Anadarko, FireEye, Bristol-Myers, Twilio and More TheStreet.com
May-02-17 05:31PM  Gilead Topples On Consensus-Lagging Q1 As Hepatitis C Drug Sales Plummet Investor's Business Daily
12:24PM  5 Things Exelixis Inc. Management Said After the Q1 Earnings Blowout That You'll Want to Know Motley Fool
May-01-17 03:42PM  ETFs with exposure to Bristol-Myers Squibb Co. : May 1, 2017 Capital Cube
08:05AM  Edited Transcript of BMY earnings conference call or presentation 27-Apr-17 2:30pm GMT Thomson Reuters StreetEvents
12:10AM  [$$] China Approves Bristol-Myers Squibbs Dual-Drug Hepatitis C Treatment The Wall Street Journal
Apr-29-17 02:07PM  2 Beaten-Up Dividend Stocks: Are They Bargains? Motley Fool
06:42AM  5 Things Bristol-Myers Squibb's Management Wants You to Know Motley Fool
Apr-28-17 05:42PM  [$$] Bristol-Myers Squibb Passes on Buyout Option for F-star Alpha The Wall Street Journal
04:38PM  Bristol-Myers Beats Gilead, Merck To Key Approvals In China, Europe Investor's Business Daily
03:59PM  Bristol-Myers Squibb: Strong Earnings Could Warrant Higher Dividend Growth Ahead GuruFocus.com
03:21PM  Despite Worries, Bristol-Myers' Opdivo Keeps Racking Up Sales Motley Fool
02:38PM  European Commission Approves Bristol-Myers Squibbs Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy Business Wire
11:43AM  [$$] China Approves Bristol-Myers Dual-Drug Hepatitis C Treatment The Wall Street Journal
11:16AM  Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 Capital Cube
10:09AM  Company News for April 28, 2017 Zacks
08:41AM  Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More Zacks
08:23AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : April 28, 2017 Capital Cube
08:21AM  Bristol-Myers wins approval in China for oral treatment for chronic hepatitis C virus MarketWatch
07:19AM  China FDA Approves Countrys First All-Oral Regimen for Chronic Hepatitis C, Daklinza® (daclatasvir) in Combination with Sunvepra® (asunaprevir) Business Wire
Apr-27-17 07:42PM  Oil's 'false tell' could set off domino effect CNBC Videos
07:01PM  Cramer: When Oil Falls, These Dominoes Get Hit TheStreet.com
06:37PM  Cramer: How oil's 'false tell' could set off a market-cha... CNBC Videos
06:11PM  Cramer: How oil's 'false tell' could set off a market-changing domino effect CNBC
05:08PM  Strong Sales for Opdivo and Eliquis Drive Bristol-Myers' Solid Q1 TheStreet.com
05:02PM  Bristol-Myers Stock Pops On Street-Crushing Q1 Revenue, Profits Investor's Business Daily
04:48PM  AbbVie Flirts With Buy Point After Q1 Earnings, Sales Top Investor's Business Daily
03:05PM  Bristol-Myers: Not Dead Yet? Barrons.com
03:00PM  Bristol-Myers Stock Pops On Street-Crushing Q1 Revenue, Profits Investor's Business Daily
01:02PM  A Refreshing Voice At Bristol-Myers Squibb Forbes
12:07PM  Biopharma earnings bonanza CNBC Videos
11:01AM  Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View Zacks
10:34AM  Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo Reuters
09:53AM  US STOCKS-Wall St little changed with eyes on earnings Reuters
08:00AM  Bristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference Business Wire
07:36AM  Analysts Ratings and Recommendations for Bristol-Myers Squibb Market Realist
07:28AM  Bristol-Myers tops Street 1Q forecasts Associated Press
07:09AM  Bristol-Myers Squibb stock surges 3% after first-quarter profit, revenue beats MarketWatch
06:59AM  Bristol-Myers beats Wall St estimates, helped by Cancer drug Opdivo Reuters
06:59AM  Bristol-Myers Squibb Reports First Quarter Financial Results Business Wire
06:35AM  Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids TheStreet.com
Apr-26-17 10:37AM  A Look at Bristol-Myers Squibbs Other Segments in 1Q17 Market Realist
09:09AM  Bristol-Myers Squibbs 1Q17 Estimates: Virology Segment Market Realist
08:04AM  Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY Zacks
07:37AM  A Look at Bristol-Myers Squibbs Oncology Segment in 1Q17 Market Realist
04:21AM  Moody's: Outlook for global pharmaceuticals industry stable on low earnings growth, new product launches Moody's
Apr-25-17 10:07PM  [$$] Aquinnah Pharmaceuticals Taps Pfizer, AbbVie for $10 Million The Wall Street Journal
06:06PM  Bristol-Myers Squibbs 1Q17 Estimates: Expect Growth! Market Realist
04:28PM  What Analysts Expect of Bristol-Myers Squibbs 1Q17 Earnings Market Realist
03:46PM  U.S. Supreme Court may limit where companies can be sued Reuters
03:09PM  U.S. Supreme Court may limit where companies can be sued Reuters
02:46PM  Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store? Zacks
01:00PM  Chill Pill: Eli Lilly Cuts Guidance with Earnings Investopedia
12:14PM  U.S. Supreme Court may limit where companies can be sued Reuters
08:04AM  3 Reasons Pfizer Is a Better Dividend Stock Than Bristol-Myers Squibb Motley Fool
06:05AM  America's 12 Most Charitable Companies Motley Fool
01:30AM  Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer Business Wire
Apr-24-17 01:52PM  NASH: The next untapped pharma market gives investors many options Reuters
09:06AM  3 Key Factors to Look Out for in Biogen's Q1 Results Zacks
07:00AM  NASH: The next untapped pharma market gives investors many options Reuters
01:00AM  NASH: The next untapped pharma market gives investors many options Reuters
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreement with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400180,458May 09 04:32 PM
ANDREOTTI LAMBERTODirectorApr 07Sale53.2217,000904,791935,571Apr 10 05:09 PM
ANDREOTTI LAMBERTODirectorApr 06Sale53.2917,000905,964952,571Apr 10 05:09 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554044,125Apr 04 07:17 PM
ANDREOTTI LAMBERTODirectorMar 28Sale56.2017,000955,369969,112Mar 29 06:19 PM
ANDREOTTI LAMBERTODirectorMar 27Sale56.1417,000954,451986,112Mar 29 06:19 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 17Sale56.495,000282,47021,483Mar 21 04:35 PM
Caldarella Joseph CSVP & ControllerMar 15Sale57.298,096463,77955,637Mar 22 06:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 14Sale56.7515,000851,22026,483Mar 16 04:37 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0087,6040199,229Mar 14 08:32 PM
Blin EmmanuelSVP, Chief Strategy OfficerMar 10Option Exercise0.0013,275023,690Mar 14 08:32 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0066,7260346,770Mar 14 08:33 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0065,4240451,862Mar 14 08:33 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,7210119,772Mar 14 08:31 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0025,592035,898Mar 14 08:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0087,3240289,293Mar 14 08:31 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.0013,696041,215Mar 14 08:30 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00102,17401,060,105Mar 14 08:30 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0031,513052,546Mar 14 08:29 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0018,799073,284Mar 14 08:29 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0033,271051,898Mar 14 08:30 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0015,484068,911Mar 14 08:29 PM
LEUNG SANDRAEVP, General CounselMar 06Sale57.0292,4055,268,563395,658Mar 07 04:39 PM
LEUNG SANDRAEVP, General CounselMar 03Option Exercise27.01116,1003,135,861488,063Mar 07 04:39 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise27.0122,598610,372212,516Mar 01 04:47 PM
Samuels Theodore R. IIDirectorFeb 27Buy56.7712,000681,24012,000Mar 01 04:47 PM
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM